Mines D`or Orbec Inc
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 375
- Market Cap
- $121.4M
- Website
- http://www.bluebirdbio.com
- Introduction
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
A Study of Participants With β-Thalassemia Treated With Betibeglogene Autotemcel
- Conditions
- Beta-Thalassemia
- Interventions
- Other: No Intervention
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 150
- Registration Number
- NCT06271512
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸UCSF Benioff Children's Hospitals, Oakland, California, United States
🇺🇸Cohen Children's Medical Center, New Hyde Park, New York, United States
A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel
- Conditions
- Cerebral Adrenoleukodystrophy (CALD)
- Interventions
- Other: No Intervention
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 120
- Registration Number
- NCT06224413
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy
- Conditions
- Sickle Cell Disease
- Interventions
- Other: Safety and efficacy assessments
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 85
- Registration Number
- NCT04628585
- Locations
- 🇺🇸
University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
🇺🇸UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease
- Conditions
- Sickle Cell Disease
- Interventions
- Genetic: bb1111
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 35
- Registration Number
- NCT04293185
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
🇺🇸Virginia Commonwealth University (VCU), Richmond, Virginia, United States
A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
- Conditions
- Cerebral Adrenoleukodystrophy (CALD)
- Interventions
- Genetic: Lenti-D
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 35
- Registration Number
- NCT03852498
- Locations
- 🇺🇸
Boston Children's Hospital/Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Lucile Packard Children's Hospital, Palo Alto, California, United States
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia
- Conditions
- Beta-Thalassemia
- Interventions
- Genetic: LentiGlobin BB305 Drug Product
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 19
- Registration Number
- NCT03207009
- Locations
- 🇮🇹
IRCCS Ospedale Pediatrico Babino Gesu, Rome, Italy
🇩🇪Hannover Medical School, Hannover, Germany
🇩🇪University of Heidelberg, Heidelberg, Germany
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype
- Conditions
- Beta-Thalassemia
- Interventions
- Genetic: LentiGlobin BB305 Drug Product
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 24
- Registration Number
- NCT02906202
Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
- Conditions
- Adrenoleukodystrophy (ALD)Cerebral Adrenoleukodystrophy (CALD)X-Linked Adrenoleukodystrophy (X-ALD)
- Interventions
- Genetic: No interventional drug product utilized in this follow-up study
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 64
- Registration Number
- NCT02698579
- Locations
- 🇺🇸
Mattel Children's Hospital-UCLA, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital - Stanford, Palo Alto, California, United States
🇺🇸Boston Children's Hospital/Massachusetts General Hospital, Boston, Massachusetts, United States
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy
- Conditions
- Transfusion-dependent Beta-Thalassemia
- Interventions
- Other: Safety and efficacy assessments
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 66
- Registration Number
- NCT02633943
Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)
- Conditions
- X-Linked Adrenoleukodystrophy (X-ALD)Cerebral Adrenoleukodystrophy (CALD)Adrenoleukodystrophy (ALD)
- Interventions
- Genetic: Allo-HSCT
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 59
- Registration Number
- NCT02204904
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States